Rationale: Treatment options for idiopathic pulmonary fibrosis (IPF) are limited. Objectives: To evaluate the efficacy and safety of BG00011, an anti-
- Raghu, G.
- Mouded, M.
- Chambers, D. C.
- Martinez, F. J.
- Richeldi, L.
- Lancaster, L. H.
- Hamblin, M. J.
- Gibson, K. F.
- Rosas, I. O.
- Prasse, A.
- Zhao, G.
- Serenko, M.
- Novikov, N.
- McCurley, A.
- Bansal, P.
- Stebbins, C.
- Arefayene, M.
- Ibebunjo, S.
- Violette, S. M.
- Gallagher, D.
- Behr, J.
Keywords
- Humans
- *Idiopathic Pulmonary Fibrosis/drug therapy
- Antibodies, Monoclonal/therapeutic use
- Treatment Outcome
- Double-Blind Method
- Immunoglobulin G
- anti-αvβ6 IgG1 monoclonal antibody
- idiopathic pulmonary fibrosis
- randomized clinical trial
- safety
- treatment efficacy
